The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib
| Autor: | Castagnetti, F, Gugliotta, G, Breccia, M, Iurlo, A, Levato, L, Albano, F, Vigneri, Paolo, Abruzzese, E, Rossi, G, Rupoli, S, Cavazzini, F, Martino, B, Orlandi, E, Pregno, P, Annunziata, M, Usala, E, Tiribelli, M, Sica, S, Bonifacio, M, Fava, C, Gherlinzoni, F, Bocchia, M, Soverini, S, Bochicchio, Mt, Cavo, M, Giovanni, M, Saglio, G, Pane, F, Baccarani, M, Rosti, G, on behalf of the GIMEMA CML Working Party |
|---|---|
| Přispěvatelé: | Castagnetti, Fausto, Gugliotta, Gabriele, Breccia, Massimo, Iurlo, Alessandra, Levato, Luciano, Albano, Francesco, Vigneri, Paolo, Abruzzese, Elisabetta, Rossi, Giuseppe, Rupoli, Serena, Cavazzini, Francesco, Martino, Bruno, Orlandi, Ester, Pregno, Patrizia, Annunziata, Mario, Usala, Emilio, Tiribelli, Mario, Sica, Simona, Bonifacio, Massimiliano, Fava, Carmen, Gherlinzoni, Filippo, Bocchia, Monica, Soverini, Simona, Bochicchio, Maria Teresa, Cavo, Michele, Giovanni, Martinelli, Saglio, Giuseppe, Pane, Fabrizio, Baccarani, Michele, Rosti, Gianantonio |
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
Oncology
Male Transcription Genetic bcr-abl Fusion Proteins bcr-abl BCR-ABL1 Chronic myeloid leukemia Philadelphia chromosome imatinib prognosis transcript type cytogenetic response 0302 clinical medicine CHRONIC-PHASE CYTOGENETIC RESPONSE MOLECULAR-BIOLOGY END-POINTS 800 MG RECOMMENDATIONS SURVIVAL CML BREAKPOINT E13A2 hemic and lymphatic diseases 80 and over Medicine molecular biology Chronic Young adult Prospective cohort study Aged 80 and over breakpoint Leukemia Philadelphia Chromosome Positive Myeloid leukemia Hematology Middle Aged Prognosis Treatment Outcome 030220 oncology & carcinogenesis Imatinib Mesylate Female Transcription prognosi medicine.drug Adult medicine.medical_specialty Adolescent Socio-culturale Antineoplastic Agents Aged Humans Leukemia Myelogenous Chronic BCR-ABL Positive Neoplasm Grading Neoplasm Staging Proportional Hazards Models Protein Kinase Inhibitors Young Adult survival 03 medical and health sciences Genetic Internal medicine end points chronic phase cytogenetic response molecular biology end points recommendations survival CML breakpoint chronic phase business.industry Proportional hazards model Fusion Proteins Imatinib medicine.disease Settore MED/15 - MALATTIE DEL SANGUE Immunology recommendations BCR-ABL Positive business Myelogenous 030215 immunology |
| Popis: | The most frequent BCR-ABL1 fusion transcripts in chronic myeloid leukemia (CML) are the e13a2 (b2a2) and the e14a2 (b3a2) ones. In the imatinib era few studies addressing the prognostic significance of the BCR-ABL1 transcript type in early chronic phase CML have been published. Overall, these studies suggest that in e14a2 patients the response to imatinib is faster and deeper. To evaluate if the BCR-ABL1 transcript type (e13a2 compared to e14a2) affect the response to imatinib and the clinical outcome in newly diagnosed adult CML patients, 559 patients enrolled in 3 prospective studies (NCT00514488, NCT00510926, observational study CML/023) were analyzed. A qualitative PCR was performed at baseline: 52% patients had a e14a2 transcript, 37% a e13a2 transcript, 11% co-expressed both transcripts and 1% had other rare transcripts. The median follow-up was 76 months (95% of the patients had at least a 5-year observation). The complete cytogenetic response rates were comparable in e14a2 and e13a2 patients. The median time to MR(3.0) (6 and 12 months) and MR(4.0) (41 and 61 months) was significantly shorter for e14a2 patients compared to e13a2 patients, with a higher cumulative probability of MR(3.0) (88% and 83%, p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|